Dosimetric predictors of diarrhea during radiotherapy for prostate cancer

Giuseppe Sanguineti, Eugene J. Endres, Maria Pia Sormani, Brent Parker

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Purpose: To investigate dosimetric predictors of diarrhea during radiotherapy (RT) for prostate cancer. Patients and Methods: All patients who underwent external-beam radiotherapy as part of treatment for localized prostate cancer at the University of Texas Medical Branch, Galveston, TX, USA, from May 2002 to November 2006 were extracted from the own database. From the cumulative dose-volume histogram (DVH), the absolute volumes (V-value) of intestinal cavity (IC) receiving 15, 30, and 45 Gy were extracted for each patient. Acute gastrointestinal toxicity was prospectively scored at each weekly treatment visit according to CTC (Common Toxicity Criteria) v2.0. The endpoint was the development of peak grade > 2 diarrhea during RT. Various patient, tumor, and treatment characteristics were evaluated using logistic regression. Results: 149 patients were included in the analysis, 112 (75.2%) treated with whole-pelvis intensity-modulated radiotherapy (WP-IMRT) and 37 (24.8%) with prostate-only RT, including or not including, the seminal vesicles (PORT ± SV). 45 patients (30.2%) developed peak grade > 2 diarrhea during treatment. At univariate analysis, IC-V15 and IC-V30, but not IC-V45, were correlated to the endpoint; at multivariate analysis, only IC-V15 (p = 0.047) along with peak acute proctitis (p = 0.041) was independently correlated with the endpoint. Conclusion: These data provide a novel and prostate treatment-specific "upper limit" DVH for IC.

Original languageEnglish (US)
Pages (from-to)390-396
Number of pages7
JournalStrahlentherapie und Onkologie
Volume185
Issue number6
DOIs
StatePublished - Jun 2009

Fingerprint

Diarrhea
Prostatic Neoplasms
Radiotherapy
Prostate
Proctitis
Therapeutics
Intensity-Modulated Radiotherapy
Seminal Vesicles
Pelvis
Multivariate Analysis
Logistic Models
Databases
Neoplasms

Keywords

  • Diarrhea
  • IMRT
  • Prostate cancer

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Oncology

Cite this

Dosimetric predictors of diarrhea during radiotherapy for prostate cancer. / Sanguineti, Giuseppe; Endres, Eugene J.; Sormani, Maria Pia; Parker, Brent.

In: Strahlentherapie und Onkologie, Vol. 185, No. 6, 06.2009, p. 390-396.

Research output: Contribution to journalArticle

Sanguineti, Giuseppe ; Endres, Eugene J. ; Sormani, Maria Pia ; Parker, Brent. / Dosimetric predictors of diarrhea during radiotherapy for prostate cancer. In: Strahlentherapie und Onkologie. 2009 ; Vol. 185, No. 6. pp. 390-396.
@article{ab3a4d5735c74429afdf5d7273dc8736,
title = "Dosimetric predictors of diarrhea during radiotherapy for prostate cancer",
abstract = "Purpose: To investigate dosimetric predictors of diarrhea during radiotherapy (RT) for prostate cancer. Patients and Methods: All patients who underwent external-beam radiotherapy as part of treatment for localized prostate cancer at the University of Texas Medical Branch, Galveston, TX, USA, from May 2002 to November 2006 were extracted from the own database. From the cumulative dose-volume histogram (DVH), the absolute volumes (V-value) of intestinal cavity (IC) receiving 15, 30, and 45 Gy were extracted for each patient. Acute gastrointestinal toxicity was prospectively scored at each weekly treatment visit according to CTC (Common Toxicity Criteria) v2.0. The endpoint was the development of peak grade > 2 diarrhea during RT. Various patient, tumor, and treatment characteristics were evaluated using logistic regression. Results: 149 patients were included in the analysis, 112 (75.2{\%}) treated with whole-pelvis intensity-modulated radiotherapy (WP-IMRT) and 37 (24.8{\%}) with prostate-only RT, including or not including, the seminal vesicles (PORT ± SV). 45 patients (30.2{\%}) developed peak grade > 2 diarrhea during treatment. At univariate analysis, IC-V15 and IC-V30, but not IC-V45, were correlated to the endpoint; at multivariate analysis, only IC-V15 (p = 0.047) along with peak acute proctitis (p = 0.041) was independently correlated with the endpoint. Conclusion: These data provide a novel and prostate treatment-specific {"}upper limit{"} DVH for IC.",
keywords = "Diarrhea, IMRT, Prostate cancer",
author = "Giuseppe Sanguineti and Endres, {Eugene J.} and Sormani, {Maria Pia} and Brent Parker",
year = "2009",
month = "6",
doi = "10.1007/s00066-009-1953-4",
language = "English (US)",
volume = "185",
pages = "390--396",
journal = "Strahlentherapie und Onkologie",
issn = "0179-7158",
publisher = "Urban und Vogel",
number = "6",

}

TY - JOUR

T1 - Dosimetric predictors of diarrhea during radiotherapy for prostate cancer

AU - Sanguineti, Giuseppe

AU - Endres, Eugene J.

AU - Sormani, Maria Pia

AU - Parker, Brent

PY - 2009/6

Y1 - 2009/6

N2 - Purpose: To investigate dosimetric predictors of diarrhea during radiotherapy (RT) for prostate cancer. Patients and Methods: All patients who underwent external-beam radiotherapy as part of treatment for localized prostate cancer at the University of Texas Medical Branch, Galveston, TX, USA, from May 2002 to November 2006 were extracted from the own database. From the cumulative dose-volume histogram (DVH), the absolute volumes (V-value) of intestinal cavity (IC) receiving 15, 30, and 45 Gy were extracted for each patient. Acute gastrointestinal toxicity was prospectively scored at each weekly treatment visit according to CTC (Common Toxicity Criteria) v2.0. The endpoint was the development of peak grade > 2 diarrhea during RT. Various patient, tumor, and treatment characteristics were evaluated using logistic regression. Results: 149 patients were included in the analysis, 112 (75.2%) treated with whole-pelvis intensity-modulated radiotherapy (WP-IMRT) and 37 (24.8%) with prostate-only RT, including or not including, the seminal vesicles (PORT ± SV). 45 patients (30.2%) developed peak grade > 2 diarrhea during treatment. At univariate analysis, IC-V15 and IC-V30, but not IC-V45, were correlated to the endpoint; at multivariate analysis, only IC-V15 (p = 0.047) along with peak acute proctitis (p = 0.041) was independently correlated with the endpoint. Conclusion: These data provide a novel and prostate treatment-specific "upper limit" DVH for IC.

AB - Purpose: To investigate dosimetric predictors of diarrhea during radiotherapy (RT) for prostate cancer. Patients and Methods: All patients who underwent external-beam radiotherapy as part of treatment for localized prostate cancer at the University of Texas Medical Branch, Galveston, TX, USA, from May 2002 to November 2006 were extracted from the own database. From the cumulative dose-volume histogram (DVH), the absolute volumes (V-value) of intestinal cavity (IC) receiving 15, 30, and 45 Gy were extracted for each patient. Acute gastrointestinal toxicity was prospectively scored at each weekly treatment visit according to CTC (Common Toxicity Criteria) v2.0. The endpoint was the development of peak grade > 2 diarrhea during RT. Various patient, tumor, and treatment characteristics were evaluated using logistic regression. Results: 149 patients were included in the analysis, 112 (75.2%) treated with whole-pelvis intensity-modulated radiotherapy (WP-IMRT) and 37 (24.8%) with prostate-only RT, including or not including, the seminal vesicles (PORT ± SV). 45 patients (30.2%) developed peak grade > 2 diarrhea during treatment. At univariate analysis, IC-V15 and IC-V30, but not IC-V45, were correlated to the endpoint; at multivariate analysis, only IC-V15 (p = 0.047) along with peak acute proctitis (p = 0.041) was independently correlated with the endpoint. Conclusion: These data provide a novel and prostate treatment-specific "upper limit" DVH for IC.

KW - Diarrhea

KW - IMRT

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=67149141700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67149141700&partnerID=8YFLogxK

U2 - 10.1007/s00066-009-1953-4

DO - 10.1007/s00066-009-1953-4

M3 - Article

VL - 185

SP - 390

EP - 396

JO - Strahlentherapie und Onkologie

JF - Strahlentherapie und Onkologie

SN - 0179-7158

IS - 6

ER -